S&P 500   4,293.37 (+0.26%)
DOW   33,679.44 (-0.25%)
QQQ   357.02 (+0.67%)
AAPL   184.20 (+1.80%)
MSFT   338.11 (+0.81%)
META   274.85 (+0.82%)
GOOGL   127.02 (+1.88%)
AMZN   125.51 (+1.01%)
TSLA   217.63 (+1.71%)
NVDA   392.52 (-0.19%)
NIO   7.67 (+1.46%)
BABA   83.67 (-0.71%)
AMD   119.07 (+1.03%)
T   15.39 (+1.18%)
F   12.63 (+1.94%)
MU   68.12 (-1.52%)
CGC   0.79 (-4.68%)
GE   104.88 (-0.87%)
DIS   90.31 (-0.51%)
AMC   4.63 (+1.76%)
PFE   38.77 (+1.07%)
PYPL   64.41 (+0.70%)
NFLX   410.01 (+2.38%)
S&P 500   4,293.37 (+0.26%)
DOW   33,679.44 (-0.25%)
QQQ   357.02 (+0.67%)
AAPL   184.20 (+1.80%)
MSFT   338.11 (+0.81%)
META   274.85 (+0.82%)
GOOGL   127.02 (+1.88%)
AMZN   125.51 (+1.01%)
TSLA   217.63 (+1.71%)
NVDA   392.52 (-0.19%)
NIO   7.67 (+1.46%)
BABA   83.67 (-0.71%)
AMD   119.07 (+1.03%)
T   15.39 (+1.18%)
F   12.63 (+1.94%)
MU   68.12 (-1.52%)
CGC   0.79 (-4.68%)
GE   104.88 (-0.87%)
DIS   90.31 (-0.51%)
AMC   4.63 (+1.76%)
PFE   38.77 (+1.07%)
PYPL   64.41 (+0.70%)
NFLX   410.01 (+2.38%)
S&P 500   4,293.37 (+0.26%)
DOW   33,679.44 (-0.25%)
QQQ   357.02 (+0.67%)
AAPL   184.20 (+1.80%)
MSFT   338.11 (+0.81%)
META   274.85 (+0.82%)
GOOGL   127.02 (+1.88%)
AMZN   125.51 (+1.01%)
TSLA   217.63 (+1.71%)
NVDA   392.52 (-0.19%)
NIO   7.67 (+1.46%)
BABA   83.67 (-0.71%)
AMD   119.07 (+1.03%)
T   15.39 (+1.18%)
F   12.63 (+1.94%)
MU   68.12 (-1.52%)
CGC   0.79 (-4.68%)
GE   104.88 (-0.87%)
DIS   90.31 (-0.51%)
AMC   4.63 (+1.76%)
PFE   38.77 (+1.07%)
PYPL   64.41 (+0.70%)
NFLX   410.01 (+2.38%)
S&P 500   4,293.37 (+0.26%)
DOW   33,679.44 (-0.25%)
QQQ   357.02 (+0.67%)
AAPL   184.20 (+1.80%)
MSFT   338.11 (+0.81%)
META   274.85 (+0.82%)
GOOGL   127.02 (+1.88%)
AMZN   125.51 (+1.01%)
TSLA   217.63 (+1.71%)
NVDA   392.52 (-0.19%)
NIO   7.67 (+1.46%)
BABA   83.67 (-0.71%)
AMD   119.07 (+1.03%)
T   15.39 (+1.18%)
F   12.63 (+1.94%)
MU   68.12 (-1.52%)
CGC   0.79 (-4.68%)
GE   104.88 (-0.87%)
DIS   90.31 (-0.51%)
AMC   4.63 (+1.76%)
PFE   38.77 (+1.07%)
PYPL   64.41 (+0.70%)
NFLX   410.01 (+2.38%)
NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Forecast, Price & News

$26.31
-1.03 (-3.77%)
(As of 11:40 AM ET)
Compare
Today's Range
$24.47
$27.50
50-Day Range
$23.15
$32.71
52-Week Range
$19.25
$39.78
Volume
385,097 shs
Average Volume
675,596 shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.33

SpringWorks Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
113.3% Upside
$56.33 Price Target
Short Interest
Bearish
25.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.46mentions of SpringWorks Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$34,839 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.92) to ($4.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

860th out of 980 stocks

Biological Products, Except Diagnostic Industry

142nd out of 163 stocks


SWTX stock logo

About SpringWorks Therapeutics (NASDAQ:SWTX) Stock

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SWTX Stock News Headlines

SpringWorks: FDA Extends PDUFA Date For Nirogacestat NDA
AI industry Is Exploding! New Breakthrough Expected this Summer
Bill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.
SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Up 11.6%
AI industry Is Exploding! New Breakthrough Expected this Summer
Bill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.
Analyst Expectations for SpringWorks Therapeutics's Future
SpringWorks Therapeutics (NASDAQ:SWTX) Trading 7.3% Higher
SpringWorks Therapeutics, Inc. (SWTX)
See More Headlines

SWTX Price History

SWTX Company Calendar

Last Earnings
5/03/2023
Today
6/05/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SWTX
Fax
N/A
Employees
176
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$56.33
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$41.00
Forecasted Upside/Downside
+106.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-277,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$35 million
Book Value
$8.95 per share

Miscellaneous

Free Float
57,878,000
Market Cap
$1.71 billion
Optionable
Not Optionable
Beta
0.57

Social Links


Key Executives

  • Mr. Saqib Islam J.D.Mr. Saqib Islam J.D. (Age 53)
    CEO & Director
    Comp: $1.13M
  • Mr. Francis I. Perier Jr. (Age 63)
    M.B.A., Chief Financial Officer
    Comp: $674.85k
  • Dr. Badreddin Edris Ph.D. (Age 36)
    Chief Operating Officer
    Comp: $844.74k
  • Mr. Bhavesh Ashar (Age 57)
    Chief Commercial Officer
    Comp: $821.61k
  • Mr. Michael P. Nofi (Age 52)
    Chief Accounting Officer
  • Ms. Kim Diamond
    VP of Communications & Investor Relations
  • Mr. Herschel S. Weinstein J.D. (Age 67)
    Gen. Counsel & Sec.
  • Mr. Daniel J. Pichl (Age 40)
    Chief People Officer
  • Dr. L. Mary Smith PH.D. (Age 56)
    Chief Devel. Officer
  • Dr. James Cassidy M.D.
    Ph.D., Chief Medical Officer













SWTX Stock - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings
or view top-rated stocks.

What is SpringWorks Therapeutics' stock price forecast for 2023?

4 Wall Street research analysts have issued 12 month price targets for SpringWorks Therapeutics' stock. Their SWTX share price forecasts range from $41.00 to $105.00. On average, they predict the company's share price to reach $56.33 in the next twelve months. This suggests a possible upside of 106.0% from the stock's current price.
View analysts price targets for SWTX
or view top-rated stocks among Wall Street analysts.

How have SWTX shares performed in 2023?

SpringWorks Therapeutics' stock was trading at $26.01 at the start of the year. Since then, SWTX stock has increased by 5.1% and is now trading at $27.34.
View the best growth stocks for 2023 here
.

When is SpringWorks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SWTX earnings forecast
.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its earnings results on Wednesday, May, 3rd. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.08. During the same quarter last year, the business earned ($1.26) earnings per share.

What other stocks do shareholders of SpringWorks Therapeutics own?
When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is SpringWorks Therapeutics' stock symbol?

SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), BlackRock Inc. (5.19%), Bain Capital Life Sciences Investors LLC (4.93%), State Street Corp (4.50%), Baker BROS. Advisors LP (4.40%) and ArrowMark Colorado Holdings LLC (4.00%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto.
View institutional ownership trends
.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SpringWorks Therapeutics' stock price today?

One share of SWTX stock can currently be purchased for approximately $27.34.

How much money does SpringWorks Therapeutics make?

SpringWorks Therapeutics (NASDAQ:SWTX) has a market capitalization of $1.71 billion and generates $35 million in revenue each year. The company earns $-277,420,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis.

How many employees does SpringWorks Therapeutics have?

The company employs 176 workers across the globe.

Does SpringWorks Therapeutics have any subsidiaries?
The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..
Read More
How can I contact SpringWorks Therapeutics?

SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The official website for the company is www.springworkstx.com. The company can be reached via phone at 203-883-9490 or via email at investors@springworkstx.com.

This page (NASDAQ:SWTX) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -